Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DEFINITELY! Just some speculation, but can you imagine the what the cross pollination of technologies between the companies $RVVTF, $IMLFF and an $OWCP could do with a couple of agreements. Dr. Friedman brings knowledge of what's going on in the Israel med MJ industry (OWCP) and RVVTF tied into $IMFF for biosynthesis WOW! I am holding my shares see what develops later on!
Not just any doctor, Dr Friedman is a leader in the field. He has also been tied in with developments in OWCP as well which had an incredible run from pennies to $3 range last few weeks and are in production. This is looking very good for Revive to bring on such a power hitter!
Looks like a slow volume day across the board multiple MJ Pharma US OTC only about a tenth of 10 Day MA. Calm before the storm?
Inmed is having a Shareholder meeting March 24th. I got a notification to vote via proxy or in person. I took a look at the "Notice of Special Meeting and Management Information Circular". It they are working to strengthen the stock grant program, shareholder voting and eliminating type A and B stock grants. Bottom line bringing the program into more compliance. I see this as a good sign they tidying and cleaning up shareholder voting and stock programs. Stock grant program to attract and reward top talent at the company, cannot exceed 20% of outstanding shares, has market price not to be below trading price and has set with black out execution vesting periods. Pretty much the norm of larger corporations! Good moves.
MM seem to be pushing PPS down with heavier sale volume- I expect a rebound soon... only hoping with some good company it will gap up versus incremental. Good news is the tree shaking out the short shares.
On Sunday @ ROTH conference, to kick start investors to start thinking and moving toward medical Marijuana investments:
Michael Abbott, Executive Chairman of Columbia Care, LLC, and Rosemary Mazanet, M.D. PhD, member of the Scientific Advisory Board of Columbia Care, LLC will make a presentation on the potential benefits from the “Medical Uses for Marijuana,” which has been legalized in many states in the US. This presentation will include a discussion of the current uses and a preview of how the product may be utilized in the future.
Steady Buying ongoing today.... stocking up for next week? Go $imlff !
ROTH Capital (Investor) Conference Next week. I am expecting some news to be released at the conference during the Inmed presentation. And a delayed PPS upward movement to begin Weds 3/14 following completion of these key discussions/ presentations. In my opinion with a volume ramp you could conservatively you could see a stock movement into the mid .30s to.40s mid week.
Monday
March 13 / 12:30- 1:30 (Pacific) Panel discussion, Medical Marijuana update
Tuesday
March 14 / 7:00am-6pm (Pacific) company presentations & breakouts
March 14 / 1:00-2:00 (Pacific) Cannibus Investing
Great DD, good YouTube video of where we're likely headed. Can't wait!!!
I wish it were true. I fell for this earlier, but after re-reading article and research I believe this to be big time fake news. The same article was out last year this one even has some out of date references from last year. One could only wish! LOL
Buyers seem to be silently loading up today.....waiting to see what's next?
Market explosion for med cannibus testors possible. Fed will move Med Cannibus/MJ to schedule three drug legalizing med in all 50 states Mar 15th! Soon to be available like everything else in your local pharmacy with Dr script. What does the future hold for $MYDX sales & stock prices? Seems to me national pharma would want tight quality controls. My hope is MYDX can capitalize on big opportunity!!!
Seeing a jump or gap up this week.
http://longlivehealthtip.online/a-big-news-trump-administration-will-legalize-marijuana-and-cannabis-on-march-15-2017/
FED to move med canibus to schedule three legalizing in all 50 US states March 15th!
What effect will this have in $RVVTF stock prices? Going up anyone? I am optimistic the market Opportunity explosion across pharma in US! Not so sure I hold on to any state Med MJ dispensaries what happens when you can just go to Rite Aide, Walgreens, CVS etc and pick up scripts just like any other med?
http://longlivehealthtip.online/a-big-news-trump-administration-will-legalize-marijuana-and-cannabis-on-march-15-2017/
FED to legalize medical marijuana in all 50 states Mar 15 ?
What could this mean for $GBLX stock price? A large gap up?
http://longlivehealthtip.online/a-big-news-trump-administration-will-legalize-marijuana-and-cannabis-on-march-15-2017/
Beware Shorts!
What will happen to stock price when medical legalized by FED in all 50 states this supposed to happen March 15! Does the market blow wide open? Hard to tell but promising never the less! Read article...thoughts?
http://longlivehealthtip.online/a-big-news-trump-administration-will-legalize-marijuana-and-cannabis-on-march-15-2017/
InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex
March 2, 2017
Vancouver, BC – March 02, 2017 - InMed Pharmaceuticals, Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announced the filing of an international Patent Cooperation Treaty (PCT) application, an important component in providing intellectual and commercial protection for INM-750 as a cannabinoid-based topical therapy for Epidermolysis Bullosa Simplex (EBS).
Epidermolysis Bullosa (EB) is a group of inherited connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears from friction or trauma. Internal organs and bodily systems can also be affected by EB. It results from a defect of anchoring between the dermis and epidermis caused most frequently by the dysfunction or absence of certain proteins in the skin. EB is an orphan disease with no known treatment and has a significant unmet medical need. INM-750 will be the first therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms.
It is well documented that cannabinoid compounds have unique anti-inflammatory, analgesic and wound healing promoting properties via several mechanisms, thus making them theoretically excellent candidates for use in alleviating some of the symptoms associated with EB. InMed’s proprietary Bioinformatics Database Assessment Tool predicted a dual approach that may prove beneficial to patients: first, the ability of certain cannabinoids to play a role in addressing key disease hallmarks (wound healing, infection, pain, itch, inflammation) in all patients with EB; and second, the ability of some cannabinoids to regulate the expression of various keratins that might compensate for the dysfunctional proteins, called keratins, that cause Epidermolysis Bullosa Simplex (EBS). EBS accounts for the vast majority of EB patients. InMed conducted several in vitro and in vivo assays and the results of these studies form the basis of this PCT application.
The Patent Cooperation Treaty (PCT) is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in each of its member states. There are 151 member countries within the PCT worldwide, so near global patent coverage can be obtained through successful patent prosecution in the U.S., Japan, Europe, Canada, Australia, New Zealand, China, Brazil, Russia, India, and many other countries. The original priority date for this filing was May 26, 2015, therefore coverage of any underlying patent claims would extend for 20 years until 2035 in the United States, and may be subject to patent term extensions that would enable years of additional protection.
"This is a significant milestone achieved by our scientific team's discovery and validation of a new cannabinoid therapy to treat serious disease with high unmet medical need. We are looking forward to fully understanding the potential impact of INM-750 in helping the EB community." said Dr. Sazzad Hossain, Chief Scientific Officer of InMed Pharmaceuticals. "The pre-clinical data emerging on the use of cannabinoids for EB, as well as other disease targets in our drug development portfolio, continue to validate our discovery approach using our bioinformatics assessment tool. These drug/disease targeting predictions are then followed by relatively quick, inexpensive, yet highly informative confirmatory laboratory studies to validate the predictions of the database. This approach is proving to be an important means to shorten drug development timelines as well as significantly reduce development costs.”
About InMed
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com
Contact: InMed Pharmaceuticals Inc.
Chris Bogart
SVP, Investor Relations and Corporate Strategy
T: 604.669.7207
E: chris@inmedpharma.com
Forward Looking Statements
This news release contains "forward-looking information" and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about the potential of cannabinoid compounds to modulate disease activity and to alleviate symptoms in EB and other diseases, the potential for this patent application to provide any intellectual property protection for InMed and the expected fundamental value drivers of the company. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Known risk factors include, among others: InMed may not use net proceeds received from the private placement as currently contemplated and InMed’s proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Copyright 2017 InMed Pharmaceuticals Inc. All rights reserved
You are receiving this email because you have subscribed to receive email updates via our website
Corporate Office: InMed Pharmaceuticals Inc.
#350-409 Granville Street
Vancouver, British Columbia
Canada V6C 1T2
T: +1.604.669.7207
F: +1.604.683.2506
info@inmedpharma.com
Unsubscribe from this list | View web version
Assuming Warrants are exercised share price can be somewhat volital in short term being warrants are ~ only 10 % of total outstanding shares. I am not worried as I assume many investor would like to see the higher gains coming in the future versus selling off and dumping the PPS versus maximizing profits. Buy & hold long get past the bumps.
Combine Roth investor meeting with RVVTF term agreement announcement later this month. PPS should move north. My opinion is They'll some additional annoucements as well as they have a fairly savvy investor team. As they move into later into Q2 possible clinical updates?
Up coming ROTH Capital Investor Conference March 12-15 . The whales may be moving in soon? Don't fret the early PPS shake out creates a buying opportunity to load up. If you are long then no worries. After all Imlff's goal is to move to NASDEQ this year, a plumpting stock would not be consistent with that goal. Just imagine what another Pharma company partner could do with a combination of tech?
29th Annual ROTH Conference Info.
Hosted by:
ROTH
March 12-15, 2017
Orange County, CA
ROTH Capital Partners invites you to join us for our 29th Annual Conference. This conference is one of the largest of its kind in the U.S. Following the success of previous year’s events, the ROTH Conference, with close
to 500 participating companies and over 4,000 attendees, will feature presentations from public and private companies in a variety of sectors.
This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a must attend event for anyone working in the small and mid-cap space.
Trade Free for 60 Days & Get Up to $600. Join E*TRADE Today!Advertisement
OWCP exec interview today http://www.cannabisfn.com/owcp-a-unique-pure-play-in-the-epicenter-of-cannabis-research-with-executive-interview/
OWCP: A Unique Pure-Play in the Epicenter of Cannabis Research (with Executive Interview)